| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
SAN DIEGO—A team of researchers from the University of California, San Diego (UCSD), have developed nanometer-sized "nanoworms" that can cruise through the bloodstream without significant interference from the body's immune defense system and home in on tumors.

The nanoworms could make it easier to image small tumors, allowing cancer to be detected and treated earlier, according to the researchers, whose findings were reported in the journal Advanced Materials.

"We hope it will allow us to locate and identify tumors at a much earlier stage in their growth," says Dr. Michael Sailor, a professor of chemistry and biochemistry at UCSD, who headed the research team, of the finding. "We also hope the materials will allow us to deliver therapies more precisely to specific targets in the body."

The scientists constructed their nanoworms from spherical iron oxide nanoparticles that join together, like segments of an earthworm, to produce tiny, gummy, worm-like structures about 30 nanometers long—or about 3 million times smaller than an earthworm. Their iron-oxide composition allows the nanoworms to show up brightly in diagnostic devices, specifically the MRI machines that are used to find tumors.

In addition to the polymer coating, which is derived from the biopolymer dextran, the scientists coated their nanoworms with a tumor-specific targeting molecule, a peptide called F3, developed in the laboratory of Erkki Ruoslahti, a cell biologist and professor at the Burnham Institute for Medical Research at UC Santa Barbara. This peptide allows the nanoworms to target and home in on tumors.

The scientists were able to verify in their experiments that their nanoworms homed in on tumor sites by injecting them into the bloodstream of mice with tumors and following the aggregation of the nanoworms on the tumors. They found that the nanoworms, unlike the spherical nanoparticles of similar size that were shuttled out of the blood by the immune system, remained in the bloodstream for hours, possibly because of the nanoworm's one-dimensional structure.

To date, nanoparticle research has been challenged by the body's natural rejections of foreign bodies, Sailor says.

"The particles have a dextran/peg coating on them that is non-sticky to opsonins, proteins the body uses to remove foreign objects," he says. "The shape seems to evade certain other clearance mechanisms, though it is unclear why at this time."

The researchers are now working on developing ways to attach drugs to the nanoworms and chemically treating their exteriors with specific chemical "ZIP codes," that will allow them to be delivered to specific tumors, organs and other sites in the body, Sailor says.

Other researchers involved in the development were Michael Schwartz of UCSD, Geoffrey von Maltzahn of MIT, and Lianglin Zhang of UC Santa Barbara. The project was funded by grants from the National Cancer Institute of the NIH.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue